Curis Inc. Common Stock (CRIS)
Stock · NASDAQ · Health Care
$0.4159as of 10/16/2026
Price chart
Active signals
CRIS Signal Track Record
How signals performed across all stocks →What CRIS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 25 | -13.0% | 36% | August 6, 2026 |
| Bollinger Band Breakout | 12 | +3.4% | 50% | February 6, 2026 |
| Volume Spike | 6 | -32.1% | 17% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +7.0% | 67% | May 29, 2024 |
| Any 20-session window (baseline) | -9.7% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipelin…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 20
- Website
- www.curis.com/
Fundamentals
- 1-day range
- $0.325$0.4533
- Market cap
- $8.59M
- P/E (trailing)
- —
- P/E (forward)
- -0.07
- EPS (trailing)
- $-14.33
- Dividend yield
- —
- Beta
- 3.57
- Avg. volume
- 230.5K
- Dividend pay date
- May 30, 2018
How Curis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Curis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.465$33.6
- INABIN8bio Inc. Common Stock$1.11▼ 6.33%Market cap $9.55MP/E —$0.88$2.73
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- BCDABioCardia Inc. Common Stock$0.92▼ 2.13%Market cap $10.80MP/E —$0.75$1.8
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.465$33.6 |
| INAB IN8bio Inc. Common Stock | $9.55M | — | $1.11 | ▼ 6.33% | $0.88$2.73 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| BCDA BioCardia Inc. Common Stock | $10.80M | — | $0.92 | ▼ 2.13% | $0.75$1.8 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Marc Rubin · July 7, 2026 · Grant6.8K @ $5.29
- Kenneth I. Kaitin · July 7, 2026 · Grant6.8K @ $5.29
- Hohneker John · July 7, 2026 · Grant6.8K @ $5.29
- GREENACRE MARTYN D · July 7, 2026 · Grant6.8K @ $5.29
- Borgman Anne Elizabeth · July 7, 2026 · Grant6.8K @ $5.29
- Diantha Duvall · July 7, 2026 · Grant48.3K @ $5.29
- Jonathan B. Zung · July 7, 2026 · Grant48.3K @ $5.29
- James E. Dentzer · July 7, 2026 · Grant110.1K @ $5.29
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Curis shares not highlighted in recent premarket movers list
Recent market reports listing top premarket movers did not include Curis, focusing instead on other stocks like Veea. The absence from this specific list indicates no major immediate news catalyst was reported for the company in that context. The stock remains in a low RSI zone, suggesting recent selling pressure, but no new fundamental changes were detailed in the provided sources.
Curis shares not highlighted in recent premarket movers list. Recent market reports listing top premarket movers did not include Curis, focusing instead on other stocks like Veea. The absence from this specific list indicates no major immediate news catalyst was reported for the company in that context. The stock remains in a low RSI zone, suggesting recent selling pressure, but no new fundamental changes were detailed in the provided sources.